Standout Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cance... 2015 2026 2018 2022 2.9k
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
    Peter Schmid, Sylvia Adams et al. New England Journal of Medicine
  2. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019)
    Fabrice André, Eva Ciruelos et al. New England Journal of Medicine
  3. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (2016)
    Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology
  4. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (2015)
    Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine
  5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
    Peter Schmid, Hope S. Rugo et al. The Lancet Oncology
  6. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018)
    Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine
  7. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020)
    Elizabeth A. Mittendorf, Hong Zhang et al. The Lancet
  8. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020)
    Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology
  9. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer (2022)
    Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine
  10. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2018)
    Sylvia Adams, Sherene Loi et al. Annals of Oncology
  11. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019)
    Stephen Johnston, Miguel Martín et al. npj Breast Cancer
  12. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 (2020)
    Fabrice André, Eva Ciruelos et al. Annals of Oncology
  13. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (2021)
    Leisha A. Emens, Sylvia Adams et al. Annals of Oncology
  14. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (2019)
    Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology
  15. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors (2020)
    Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery
  16. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021)
    Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute
  17. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies (2022)
    Charles A. Powell, Shanu Modi et al. ESMO Open
  18. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022)
    Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research

Immediate Impact

3 by Nobel laureates 9 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
5 intermediate papers

Works of Hiroji Iwata being referenced

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
2019 Standout
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
2018
and 4 more

Author Peers

Author Last Decade Papers Cites
Hiroji Iwata 16179 9284 6860 514 22.9k
Masakazu Toi 10580 5860 6747 651 20.9k
Mario Campone 14956 8736 6936 532 23.2k
Javier Cortés 20283 8493 7648 709 27.3k
Karen A. Gelmon 15458 6371 6840 389 23.1k
Pierfranco Conté 16376 7447 6245 684 25.1k
Sibylle Loibl 19027 8106 13044 584 28.4k
Seock‐Ah Im 23147 13475 8677 652 31.7k
John Crown 12728 4664 5824 413 19.6k
Nancy U. Lin 10838 7494 3908 368 16.5k
Nadia Harbeck 19898 11633 12822 839 32.4k

All Works

Loading papers...

Rankless by CCL
2026